We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00823680
Recruitment Status : Completed
First Posted : January 16, 2009
Last Update Posted : July 28, 2016
Information provided by (Responsible Party):

January 15, 2009
January 16, 2009
July 28, 2016
April 2009
August 2009   (Final data collection date for primary outcome measure)
Absolute change in mean daily plasma glucose [ Time Frame: From baseline to day 27 ]
Same as current
Complete list of historical versions of study NCT00823680 on ClinicalTrials.gov Archive Site
  • Fasting plasma glucose [ Time Frame: Baseline, and weeks 1, 2, 3 and 4 ]
  • Post-prandial glucose and insulin [ Time Frame: Baseline, weeks 2 and 4 ]
  • Insulin sensitivity, beta cell function, lipid profile, HbA1C [ Time Frame: At baseline, and at planned visits up to week 4 ]
  • Adverse events, lab parameters, vital signs, body weight [ Time Frame: At baseline, and at planned visits up to week 4 ]
Same as current
Not Provided
Not Provided
A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Multi-center, Randomized, Double-blind, 5-arm Parallel Group, Placebo Controlled 4 Week Study to Investigate the Safety, Tolerability and Efficacy of Two Doses Each (Near to Maximum Tolerated Dose and Lower Dose) of RO5093151 Administered Twice Daily (BID Regimen) and RO5027838 Administered Once da
This 5 arm study will evaluate the efficacy and safety of RO5093151 and RO5027838 in patients with type 2 diabetes mellitus on a stable dose of metformin. After a 4 week pre-randomization period for glucose control, patients will be randomized to one of 5 groups to receive a)RO5093151 400mg po bid b)RO5093151 10mg po bid c)RO5027838 200mg po qd d)RO5027838 50mg po qd or e)placebo po bid for 4 weeks. The anticipated time on study treatment is < 3 months, and the target sample size is 100-500 individuals.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus Type 2
  • Drug: Placebo
    po bid for 4 weeks
  • Drug: RO5027838
    200mg po qd for 4 weeks
  • Drug: RO5027838
    50mg po bid for 4 weeks
  • Drug: RO5093151
    400mg po bid for 4 weeks
  • Drug: RO5093151
    10mg po bid for 4 weeks
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: RO5027838 200mg
    Intervention: Drug: RO5027838
  • Experimental: RO5027838 50mg
    Intervention: Drug: RO5027838
  • Experimental: RO5093151 10mg
    Intervention: Drug: RO5093151
  • Experimental: RO5093151 400mg
    Intervention: Drug: RO5093151
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • adult patients, 35-65 years of age;
  • type 2 diabetes for >=3 months;
  • treated for >=3 months with stable dose of metformin >=1.5g/day or maximum tolerated dose.

Exclusion Criteria:

  • history of diabetic ketoacidosis;
  • currently or previously treated with insulin;
  • currently or within previous 6 months treated with a thiazolidinedione or dual peroxisome proliferator activated receptor (PPAR) agonist;
  • treated with lipoprotein-modifying therapy within a month before screening.
Sexes Eligible for Study: All
35 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Austria,   Germany,   United States
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP